ZYME

#1967
Zymeworks Inc.
27.1571 USD
+3.77%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
27.1500
27.1900
Intervallo Annuale
16.0034
28.4900
Variazione giornaliera
+3.77%
Variazione Mensile
+17.21%
Variazione di 6 mesi
+53.08%
Variazione Annuale
+53.08%
Chiusura Precedente
26.1700
Apertura
27.1500
Bid
Ask
Minimo
27.1500
High
27.1900
Volume
4
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 2.0028 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-24.38
Rapporto prezzo/fatturato
18.74

Zymeworks Inc

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

Notizie